Table 2 Overview over histone deacetylase inhibitors and their properties cited in this review

AN-1

Butyroyloxymethyl butyrate

Short-chain fatty acid

N/A

–

–

AN-9

Pivaloylomethyl butyrate

Pivanex®

Short-chain fatty acid

N/A

Phase I, II (CLL, MM, NSCLC)

n = 3 (NA 3)

NaB

Sodium-butyrate

Short-chain fatty acid

Class I, IIa

–

–

PB

Phenylbutyrate

Short-chain fatty acid

Class I, IIa

Phase I, II (AML, MDS, NSCLC, colorectal cancer)

n = 9 (NA 9)

VA

Valproic acid

Depakote®, Convulex®, Orfiril®, Stavzor®

Short-chain fatty acid

Class I

Phase I, II (hematologic neoplasias, solid tumours)

n = 45^b (A 23, NA 22)

AAHA

Azelaic-1-hydroxamate-9-anilide

Hydroxamate

N/A

–

–

ABHA

Azelaic bishydroxamic acid

Hydroxamate

N/A

–

–

CBHA

m-Carboxycinnamic acid bis-hydroxamide

Hydroxamate

N/A

–

–

PCI-24781

Hydroxamate

Class I, IIb

Phase I, II (hematologic neoplasias, sarcoma)

n = 5 (A 2, NA 3)

SAHA

Suberoylanilide hydroxamic acid

Vorinostat®, Zolinza®

Hydroxamate

Class I, IIa, b

Phase I, II, III (hematologic neoplasias, solid tumours)

n = 159 (A 78, NA 81)

SBHA

Suberic bishydroxamate

Hydroxamate

N/A

–

–

TSA

Trichostatine A

Hydroxamate

Class I, IIa, b

–

–

MS275

SNDX-275, Etinostat

Benzamide

Class I, IIa

Phase I, II (hematologic neoplasias/solid tumours)

n = 9 (A 3, NA 6)